Company intelligence / Profile preview
Neuramedy
Seoul, Seoul, South Koreaneuramedy.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead asset Tomaralimab/NM‑101 targeting TLR2 has shown promise in preclinical models of synucleinopathies. The company has entered a major collaboration with Bioasis to enhance brain delivery using the xB^3TM platform. Clinical trials have not yet commenced as of the latest updates.
- Therapeutic areas
- HematologyOncologyNeurology
- Modalities
- Monoclonal antibodies (e.g., Tomaralimab)Small moleculesAptamers (via partnership)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Bioasis Technologies Inc. – collaboration on xB^3TM blood-brain barrier delivery platform for enhanced brain penetration of antibodies like Tomaralimab.Amyloid Solution – R&D partnership focused on Alzheimer’s disease research.Aptamer Sciences – Partnership to improve antibody technologies using aptamers.Yungjin Pharm – Collaboration on lead compound discovery for Parkinson's disease.
Beyond the preview
Go deeper on Neuramedy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuramedy.